ΜΑΝΟΛΗΣ ΣΙΝΑΚΟΣ

Δημοσιεύσεις

1: Gigi E, Lalla T, Orphanou E, Sinakos E, Vrettou E, Raptopoulou-Gigi M. Long term follow-up of a large cohort of inactive HBsAg (+)/ HBeAg (-)/ anti-HBe (+) carriers in Greece. J Gastrointestin Liver Dis. 2007 Mar;16(1):19-22. PMID: 17410284.

2: Gigi E, Sinakos E, Lalla T, Vrettou E, Orphanou E, Raptopoulou M. Treatment of intravenous drug users with chronic hepatitis C: treatment response, compliance and side effects. Hippokratia. 2007 Oct;11(4):196-8. PMID: 19582193; PMCID: PMC2552983.

3: Gigi E, Raptopoulou-Gigi M, Kalogeridis A, Masiou S, Orphanou E, Vrettou E, Lalla TH, Sinakos E, Tsapas V. Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease. J Viral Hepat. 2008 Feb;15(2):145-54. doi: 10.1111/j.1365-2893.2007.00908.x. PMID: 18184198.

4: Televantou D, Sinakos E, Akriviadis EA, Hytiroglou P. Toxic hepatic injury mimicking ascending cholangitis: is Pyrus amygdaliformis to blame? Virchows Arch. 2008 Oct;453(4):413-5. doi: 10.1007/s00428-008-0663-0. Epub 2008 Sep 12. PMID: 18787839.

5: Sykia A, Gigi E, Sinakos E, Bibashi E, Bellou A, Raptopoulou-Gigi M. Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg- interferon-a and ribavirin. J Gastrointestin Liver Dis. 2009 Mar;18(1):118-9. PMID: 19337648.

6: Chourmouzi D, Sinakos E, Papalavrentios L, Akriviadis E, Drevelegas A. Gastrointestinal stromal tumors: a pictorial review. J Gastrointestin Liver Dis. 2009 Sep;18(3):379-83. PMID: 19795038.

7: Fotiadu A, Gagalis A, Akriviadis E, Kotoula V, Sinakos E, Karkavelas G, Hytiroglou P. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. Pathol Int. 2010 Feb;60(2):87-92. doi: 10.1111/j.1440-1827.2009.02489.x. PMID: 20398192.

8: Sinakos E, Lindor KD. Bile acid profiles in intrahepatic cholestasis of pregnancy: is this the solution to the enigma of intrahepatic cholestasis of pregnancy? Am J Gastroenterol. 2010 Mar;105(3):596-8. doi: 10.1038/ajg.2009.639. PMID: 20203641.

9: Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. Scand J Gastroenterol. 2010 Apr;45(4):511-2. doi: 10.3109/00365521003628335. PMID: 20113152.

10: Sinakos E, Gigi E, Lalla T, Bellou AL, Sykja A, Orphanou E, Vrettou E, Tsapas V, Raptopoulou M. Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment. Hippokratia. 2010 Apr;14(2):122-5. PMID: 20596269; PMCID: PMC2895284.

11: Sinakos E, Perifanis V, Vlachaki E, Tsatra I, Raptopoulou-Gigi M. Is liver stiffness really unrelated to liver iron concentration? Br J Haematol. 2010 Jul;150(2):247-8. doi: 10.1111/j.1365-2141.2010.08183.x. Epub 2010 Apr 4. PMID: 20377588.

12: Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Janssen HL; PARC Study Group. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol. 2010 Aug;105(8):1762-9. doi: 10.1038/ajg.2010.186. Epub 2010 May 11. PMID: 20461068.

13: Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology. 2010 Jul;52(1):197-203. doi: 10.1002/hep.23631. PMID: 20564380; PMCID: PMC2928060.

14: Sinakos E, Lindor K. Treatment options for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):473-88. doi: 10.1586/egh.10.33. PMID: 20678020.

15: Thackeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011 Jan;9(1):52-6. doi: 10.1016/j.cgh.2010.09.020. Epub 2010 Oct 1. PMID: 20920596.

16: Paschos P, Vlachaki E, Pasvanti C, Sinakos E, Kalpaka A, Klonizakis P, Perifanis V. Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience. Acta Haematol. 2011;126(4):231-3. doi: 10.1159/000330516. Epub 2011 Sep 21. PMID: 21934299.

17: Sinakos E, Selvaggi G, Papalavrentios L, Tzakis A, Akriviadis E. The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence. Ann Gastroenterol. 2011;24(3):228-230. PMID: 24713719; PMCID: PMC3959316.

18: Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol. 2011 May;9(5):434-9.e1. doi: 10.1016/j.cgh.2011.02.007. Epub 2011 Feb 17. PMID: 21334457.

19: Sinakos E, Papalavrentios L, Chourmouzi D, Dimopoulou D, Drevelegas A, Akriviadis E. The clinical presentation of Von Meyenburg complexes. Hippokratia. 2011 Apr;15(2):170-3. PMID: 22110302; PMCID: PMC3209683.

20: Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD. High- dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011 Sep;106(9):1638-45. doi: 10.1038/ajg.2011.156. Epub 2011 May 10. PMID: 21556038; PMCID: PMC3168684.

21: Ali AH, Sinakos E, Silveira MG, Jorgensen RA, Angulo P, Lindor KD. Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol. 2011 Aug;45(7):e66-71. doi: 10.1097/MCG.0b013e3181f18c4e. PMID: 20856137.

22: Sinakos E, Abbas G, Jorgensen RA, Lindor KD. Serum lipids in primary sclerosing cholangitis. Dig Liver Dis. 2012 Jan;44(1):44-8. doi: 10.1016/j.dld.2011.07.020. Epub 2011 Sep 3. PMID: 21890438.

23: Imam MH, Sinakos E, Gossard AA, Kowdley KV, Luketic VA, Edwyn Harrison M, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, DeCook AC, Enders F, Lindor KD. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011 Nov;34(10):1185-92. doi: 10.1111/j.1365-2036.2011.04863.x. Epub 2011 Sep 29. PMID: 21957881; PMCID: PMC3752281.

24: Imam MH, Silveira MG, Sinakos E, Gossard AA, Jorgensen R, Keach J, DeCook AC, Lindor KD. Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012 Feb;10(2):182-5. doi: 10.1016/j.cgh.2011.09.013. Epub 2011 Oct 1. PMID: 21963959.

25: Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int. 2012 May;32(5):790-5. doi: 10.1111/j.1478-3231.2011.02678.x. Epub 2011 Dec 4. PMID: 22136310.

26: Sinakos E, Vlachaki E, Tsapas A. Safety of deferasirox in sickle cell disease patients with co-existing liver impairment. Br J Haematol. 2012 May;157(4):505-6; author reply 506-7. doi: 10.1111/j.1365-2141.2012.09040.x. Epub 2012 Feb 2. PMID: 22299817.

27: Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012 Jul;27(7):1150-8. doi: 10.1111/j.1440-1746.2012.07109.x. PMID: 22413872.

28: Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE, Janssen HL; PARC Study Group. Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders. Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1012-9. doi: 10.1097/MEG.0b013e3283557e23. PMID: 22668876.

29: Gigi E, Sykia A, Sinakos E, Koumerkeridis G, Raptopoulou-Gigi M, Bellou A, Mougiou D, Orfanou E, Vrettou E. Virologic response and resistance to lamivudine in patients with chronic hepatitis B: a ten-year retrospective analysis. Hippokratia. 2012 Oct;16(4):342-6. PMID: 23935314; PMCID: PMC3738609.

30: Gigi E, Sinakos E, Sykja A, Androulakis G, Tanis C, Stayridou V, Tsirogianni E, Zouridakis K, Bellou AL, Orfanou E, Raptopoulou-Gigi M. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. J Addict Med. 2013 Jan-Feb;7(1):52-7. doi: 10.1097/ADM.0b013e318279756f. PMID: 23340710.

31: Sinakos E, Samuel S, Enders F, Loftus EV Jr, Sandborn WJ, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis. 2013 Apr;19(5):1004-9. doi: 10.1097/MIB.0b013e3182802893. PMID: 23502353.

32: Papalavrentios L, Sinakos E, Chourmouzi D, Hytiroglou P, Drevelegas K, Drevelegas A, Akriviadis E. 3 Tesla diffusion-weighted MRI for assessing liver fibrosis in nonalcoholic fatty liver disease. Hepatology. 2013 Jul;58(1):449-50. doi: 10.1002/hep.26220. PMID: 23299663.

33: Treeprasertsuk S, Björnsson E, Sinakos E, Weeding E, Lindor KD. Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy. World J Gastrointest Pharmacol Ther. 2013 Aug 6;4(3):61-8. doi: 10.4292/wjgpt.v4.i3.61. PMID: 23919218; PMCID: PMC3729869.

34: Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol. 2014 Apr 27;6(4):178-87. doi: 10.4254/wjh.v6.i4.178. PMID: 24799986; PMCID: PMC4009473.

35: Papalavrentios L, Sinakos E, Chourmouzi D, Hytiroglou P, Drevelegas K, Constantinides M, Drevelegas A, Talwalkar J, Akriviadis E. Value of 3 Tesla diffusion-weighted magnetic resonance imaging for assessing liver fibrosis. Ann Gastroenterol. 2015 Jan-Mar;28(1):118-123. PMID: 25608776; PMCID: PMC4289984.

36: Papachrysos N, Hytiroglou P, Papalavrentios L, Sinakos E, Kouvelis I, Akriviadis E. Antiviral therapy leads to histological improvement of HBeAg- negative chronic hepatitis B patients. Ann Gastroenterol. 2015 Jul- Sep;28(3):374-378. PMID: 26126929; PMCID: PMC4480175.

37: Sinakos E, Hytiroglou P, Chourmouzi D, Akriviadis E. Focal nodular hyperplasia in an individual with Abernethy malformation type 1b. Dig Liver Dis. 2015 Dec;47(12):1089. doi: 10.1016/j.dld.2015.07.046. Epub 2015 Aug 6. PMID: 26341965.

38: Papachrysos N, Hytiroglou P, Papalavrentios L, Sinakos E, Kouvelis I, Akriviadis E. Authors' reply. Ann Gastroenterol. 2015 Oct-Dec;28(4):507. PMID: 26423354; PMCID: PMC4585406.

39: Manolakopoulos S, Kranidioti H, Goulis J, Vlachogiannakos J, Elefsiniotis J, Kouroumalis EA, Koskinas J, Kontos G, Evangelidou E, Doumba P, Sinakos E, Vafiadou Ι, Koulentaki M, Papatheodoridis G, Akriviadis E. Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. Ann Gastroenterol. 2015 Oct-Dec;28(4):481-6. PMID: 26423714; PMCID: PMC4585396.

40: Gbandi E, Goulas A, Sevastianos V, Hadziyannis S, Panderi A, Koskinas J, Papatheodoridis G, Vasiliadis T, Agapakis D, Protopapas A, Ioannidou P, Zacharakis G, Sinakos E, Koutsounas S, Germanidis G. Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. Pharmacol Rep. 2016 Apr;68(2):476-82. doi: 10.1016/j.pharep.2015.10.009. Epub 2015 Nov 6. PMID: 26922556.

41: Sinakos E, Antoniadis N, Goulis I, Cholongitas E, Kiapidou S, Tsakni E, Vasiliadis T, Papanikolaou V, Akriviadis E. Nucleos(t)ide analogues for the prevention of hepatitis B recurrence after liver transplantation do not affect serum phosphorus levels. Ann Gastroenterol. 2016 Apr-Jun;29(2):208-13. doi: 10.20524/aog.2016.0014. PMID: 27065734; PMCID: PMC4805742.

42: Akriviadis E, Sinakos E. Treatment of alcoholic hepatitis: is this a "dead- end"? Ann Gastroenterol. 2016 Apr-Jun;29(2):236-7. doi: 10.20524/aog.2016.0023. PMID: 27065743; PMCID: PMC4805751.

43: Cholongitas E, Ioannidou M, Goulis I, Chalevas P, Ntogramatzi F, Athanasiadou Z, Notopoulos A, Alevroudis M, Sinakos E, Akriviadis E. Comparison of creatinine and cystatin formulae with ⁵¹ Chromium- ethylenediaminetetraacetic acid glomerular filtration rate in patients with decompensated cirrhosis. J Gastroenterol Hepatol. 2017 Jan;32(1):191-198. doi: 10.1111/jgh.13446. PMID: 27177318.

44: Soulaidopoulos S, Sinakos E, Dimopoulou D, Vettas C, Cholongitas E, Garyfallos A. Anticholinergic syndrome induced by toxic plants. World J Emerg Med. 2017;8(4):297-301. doi: 10.5847/wjem.j.1920-8642.2017.04.009. PMID: 29123609; PMCID: PMC5675972.

45: Sousos N, Sinakos E, Klonizakis P, Adamidou D, Daniilidis A, Gigi E, Vetsiou E, Tsioni K, Mandala E, Vlachaki E. Deferasirox improves liver fibrosis in beta- thalassaemia major patients. A five-year longitudinal study from a single thalassaemia centre. Br J Haematol. 2018 Apr;181(1):140-142. doi: 10.1111/bjh.14509. Epub 2017 Jan 20. PMID: 28106901.

46: Sinakos E, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct- acting antivirals in patients with β-thalassaemia major and advanced liver disease. Br J Haematol. 2017 Jul;178(1):130-136. doi: 10.1111/bjh.14640. Epub 2017 Apr 25. PMID: 28439915.

47: Louvet A, Thursz MR, Kim DJ, Labreuche J, Atkinson SR, Sidhu SS, O'Grady JG, Akriviadis E, Sinakos E, Carithers RL Jr, Ramond MJ, Maddrey WC, Morgan TR, Duhamel A, Mathurin P. Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. Gastroenterology. 2018 Aug;155(2):458-468.e8. doi: 10.1053/j.gastro.2018.05.011. Epub 2018 May 5. PMID: 29738698.

48: Kalogirou M, Chourmouzi D, Dedes I, Kiapidou S, Akriviadis E, Sinakos E. Transarterial embolization for the treatment of complicated liver hemangiomas: A report of two cases and review of the literature. Clin Mol Hepatol. 2018 Sep;24(3):345-349. doi: 10.3350/cmh.2017.0075. Epub 2018 Jun 11. PMID: 29886705; PMCID: PMC6166110.

49: Sinakos Ε, Gioula G, Liava C, Papa A, Papadopoulou E, Tsakni E, Fouzas I, Akriviadis E. Prevalence of hepatitis E in liver transplant recipients in Greece. Epidemiol Infect. 2018 Oct;146(13):1619-1621. doi: 10.1017/S0950268818001887. Epub 2018 Jul 5. PMID: 29974836.

50: Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol. 2018 Nov 27;10(11):790-794. doi: 10.4254/wjh.v10.i11.790. PMID: 30533179; PMCID: PMC6280165.

51: Sinakos E, Hytiroglou P, Stachteas P, Liava C, Akriviadis E. The significance of paired biopsies in estimating disease progression in patients with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2019 Jul;31(7):897-898. doi: 10.1097/MEG.0000000000001412. PMID: 31149958.

52: Gioula G, Sinakos E, Gigi E, Goulis I, Vasiliadis T, Minti F, Akriviadis E. 'Distribution of Hepatitis C Virus genotypes in northern Greece in the last decade: descriptive analysis and clinical correlations'. Glob Health Epidemiol Genom. 2019 Sep 2;4:e5. doi: 10.1017/gheg.2019.4. PMID: 31516719; PMCID: PMC6719250.

53: Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol. 2020 Mar-Apr;19(2):134-144. doi: 10.1016/j.aohep.2019.07.013. Epub 2019 Sep 23. PMID: 31606352.

54: Protopapas AA, Papagiouvanni I, Fragkou N, Alevroudis E, Sinakos E, Goulis I. Estimation of glomerular filtration rate in patients with cirrhosis: evaluation of equations currently used in clinical practice and validation of Royal Free Hospital cirrhosis glomerular filtration rate. Eur J Gastroenterol Hepatol. 2020 Sep 17. doi: 10.1097/MEG.0000000000001935. Epub ahead of print. PMID: 32956187.

55: Kalogirou MS, Patoulias D, Haidich AB, Akriviadis E, Sinakos E. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2020 Dec 11:S2210-7401(20)30309-0.. Epub ahead of print. PMID: 33309563

56: Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13. PMID: 33185364